Target intelligence / Profile preview

Sperm flagellar protein 2 (SPEF2)

Target
SPEF2
Molecular classification
Other (structural axonemal/ciliary-associated protein)
01

Overview

Sperm flagellar protein 2 (SPEF2) is a structural and functional protein required for the assembly and integrity of the axoneme—the core cytoskeletal structure of sperm flagella and motile cilia[1][3]. It is essential for normal sperm motility and morphology, acting as a component of the central pair complex and interacting with proteins involved in intra-flagellar transport (IFT), such as IFT20, and axonemal radial spoke proteins like RSPH9[1][2]. SPEF2 is broadly expressed in ciliated tissues (testis, lung, brain, trachea, spleen) and has additional roles in osteoblast differentiation and bone formation, implicated via cilia-related signaling and protein transport[2]. Loss-of-function mutations cause severe male infertility (MMAF), primary ciliary dyskinesia, and skeletal abnormalities, but currently, there are no approved drugs targeting SPEF2 nor is it considered a therapeutic target. SPEF2's primary importance is as a structural protein and a genetic factor in the pathogenesis of certain ciliopathies and infertility syndromes, making it a valuable biomarker but not a classic druggable target[1][2][3].

Other names
KIAA1770KPL2FLJ23577CT122Cancer/testis antigen 122SPGF43Li 47atestis tissue sperm-binding protein Li 47aProtein KPL2
02

Biological functions

Flagellar assemblySperm motilityDifferenti-ation of ciliated tissues (including osteoblasts)Cellular protein and vesicle transport along microtubules
03

Disease associations

Male infertility (severe asthenoteratozoospermia, multiple morphological abnormalities of the sperm flagella, MMAF)Primary ciliary dyskinesia (PCD)Growth defects/developmental disorders (mouse models)Other (possible skeletal abnormalities via osteoblast dysfunction)
04

Safety considerations

Loss-of-function mutations result in infertility but no safety concerns for therapeutic intervention are described, as SPEF2 is not currently a therapeutic target.Functional deficiency in SPEF2 causes PCD symptoms and, in mouse models, severe hydrocephalus and skeletal abnormalities.
05

Biomarkers

Potential biomarker for male infertility (mutations or severe loss-of-function in SPEF2 are diagnostic for MMAF and PCD-related infertility)

Beyond the preview

Go deeper on Sperm flagellar protein 2 (SPEF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sperm flagellar protein 2 (SPEF2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call